anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
<P>PROBLEM TO BE SOLVED: To refer to information by display means of a plurality of ultrasonic image diagnostic apparatuses with different specifications in a networked ultrasonic image diagnostic system by unitarily managing/controlling the information including image information and reports, etc. by a report server.  <P>SOLUTION: The ultrasonic image diagnostic system comprises the ultrasonic image diagnostic apparatus 1 with the display means 141 for displaying at least real-time ultrasonic image information of a subject, an image information server 4 for accumulating the already obtained ultrasonic image information as second image information corresponding to the identification information of the subject, and the report server 2 for accumulating report information. The ultrasonic image diagnostic apparatus 1, the image information server 4 and the report server 2 are connected with a network 5. The report server 2 makes the image information server 4 extract the second image information based on the identification information, and makes the display means 141 display the second image information and the report information based on the identification information.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
Dental appointment, one hour and included activities that are normally part of a SPT consultation, as well as specific behavior change techniques, such as the use of reinforcement, goal-setting and feedback.. Participants in the SMS group further received a total of 16 messages (SMS). One per week.
Participants receive 3 preoperative cycles of pembrolizumab, followed by standard of care surgery, followed by 14 cycles of postoperative pembrolizumab. Each cycle is 21 days.
Elevations of transaminases may occur in PONVORY-treated patients.

Obtain transaminase and bilirubin levels, if not recently available (i.e., within last 6 months) before initiation of PONVORY.

In Study 1, elevations of ALT to 5-fold the upper limit of normal (ULN) or greater occurred in 4.6% of patients treated with PONVORY compared to 2.5% of patients who received teriflunomide 14 mg. Elevation of ALT to 3-fold the ULN or greater occurred in 17.3% of patients treated with PONVORY and 8.3% of patients treated with teriflunomide 14 mg. The median time to an elevation of 3-fold the ULN was 3 months. The majority (89%) of patients with ALT increases 3-fold or greater the ULN continued treatment with PONVORY with values returning to less than three times the ULN within approximately 2-4 weeks.

In Study 1, the discontinuation rate because of elevations in hepatic enzymes was 2.3% of patients treated with PONVORY and 1.9% of patients who received teriflunomide 14 mg.

Patients who develop symptoms suggestive of hepatic dysfunction, such as unexplained nausea, vomiting, abdominal pain, fatigue, anorexia, rash with eosinophilia, or jaundice and/or dark urine during treatment, should have hepatic enzymes checked. PONVORY should be discontinued if significant liver injury is confirmed.

No dosage adjustment is necessary in patients with mild hepatic impairment (Child-Pugh class A). PONVORY is not recommended in patients with moderate or severe hepatic impairment (Child- Pugh class B and C, respectively) [see Use in Specific Populations (8.6) and Clinical Pharmacology (12.3)].
PURPOSE:To obtain the titled substance containing absorbable calcium, by converting a system of calcium carbonate, e.g., a shell, egg-shell, etc. into a system of calcium oxide by heat treatment, followed by blending the system with a food, drug, feed, etc. CONSTITUTION:A system of calcium carbonate, e.g., a shell such as a scallop, etc., coral, eggshell, etc. is converted into calcium oxide or a composition consisting essentially of calcium oxide by heating. Calcium oxide or the composition is reacted or blended or impregnated with water, steam, carbonate, e.g., calcium carbonate, etc., edible organic acid, e.g., brewed vingar, etc., component of medicinal herb, e.g., neem tree, etc., drug, food, feed, or fertilizer, and the precipitate is removed. The solution is then heated or dried to give a solid substance or liquid useful as a drug, food, cosmetic, feed, fertilizer, etc. Since calcium is contained in a state to be ionized readily, it is apt to be absorbed in the body, and it contains other minerals.
FIELD: medicine. ^ SUBSTANCE: claimed invention relates to medicine. Described is composition for transcutaneous absorption of denepezil or its hydrochloride. Composition for transcutaneous absorption includes 2-[(1-benzyl-4-pyperidinyl)methyl]-5,6-dimethoxyindan-1-on and/or its hydrochloride and chloride of metal in layer of adhering under pressure glue preparation, which was subjected to linking. ^ EFFECT: composition is stable and resistant to loss of cohesive ability of layer adhering with pressure on glue preparation, when applied, and is resistant to adhesive transfer resulting from cohesive destruction during removal by exfoliation. ^ 10 cl, 12 ex
PURPOSE:To obtain a high-purity pertussis toxin (PT) and fibrous hemagglutinin (F-HA) in high yield at an extremely low cost, by cultivating Bordetella pertussis in a culture medium containing cellulose (derivative). CONSTITUTION:Cellulose or a derivative thereof or both are added and blended with a basal culture medium (e.g. Cohen.Wheeler culture medium) used for cultivating Bordetella pertussis so as to provide 0.01-2.0wt.% final concentration and the Bordetella pertussis is cultivated in the resultant modified culture medium at 30-37 deg.C for 20-80hr. The obtained culture is subsequently separated into a cultivation supernatant and microbial cells. The above-mentioned cultivation supernatant is then purified to recover PT and F-HA. Formalin is subsequently added and mixed to detoxify the purified PT and F-HA fraction and formalin is removed by dialysis. The resultant dialyzate is diluted with a phosphoric acid buffer solution, etc., to provide a vaccine concentrate, which is then used to prepare a mixed vaccine. Gelatin (derivative) in an amount of 0.1-5.0wt.% as a stabilizer is added to remarkably improve heat and cold resistance.
Clinical activity management is provided by a patient activity list that allows rescheduling of clinical activities in context. A timeline view is presented including one or more scheduled clinical activities for at least one patient assigned to the clinician. The timeline view is divided into a number of time periods and each scheduled clinical activity is presented at a time period corresponding with a scheduled time for the scheduled clinical activity. User input indicating a desire to reschedule at least one scheduled clinical activity is received, and a rescheduling user interface component is presented in conjunction with the timeline view. Further user input is received indicating a change in scheduled time for the scheduled clinical activity via the rescheduling user interface component. In response to the further user input, the scheduled clinical activity is presented at a time period in the timeline view based on the change in scheduled time.
Tape placing will consider as the initial anchor the acromioclavicular joint, and as the final one the point immediately below the insertion of the deltoid muscle. Two centimeters anchor will be considered for all the participants, and the active zone will be equivalent to the distance between two anchors. The first tape will be placed to the anterior portion of the deltoid with the shoulder at 30° passive extension. The second tape will be placed to the middle portion of the deltoid with the shoulder at 30° of passive horizontal adduction. For placing the third tape to the posterior deltoid, the limb will be positioned at 90° of passive flexion of the shoulder. The elastic tape tension will be placed as previously described as "paper tension" and it is equivalent to 10-15% of the total elastic tape tension.
BACKGROUND: Although the rate of venous thromboembolism (VTE) after foot and ankle surgery is low, multiple factors influence risk for individual patients. Furthermore, there are no clear guidelines on which patients may benefit from chemical thromboprophylaxis. Our aim was to assess patients not treated with chemical thromboprophylaxis after foot and ankle surgery, and to report on their specific patient and surgical risk factors for VTE.
METHODS: This was a multicenter, prospective, national audit of patients undergoing foot and ankle surgery (including Achilles tendon ruptures) from 68 participating UK centers. The study was conducted between June 1, 2022, and November 30, 2022, with a further 3-month follow-up. Following data cleansing, 3309 patients were included who did not receive postoperative thromboprophylaxis.
RESULTS: Most patients were elective cases (2589 patients, 78.24%) with ASA grade I or II (2679 patients, 80.96%), fully weightbearing postoperatively (2752 patients, 83.17%), and either without ankle splintage, or splinted in a plantigrade boot (2797 patients, 84.53%). The VTE rate was 0.30% overall (11 cases), with no VTE-related mortality. No single demographic, surgical, or postoperative factor was associated with reduced risk of VTE. However, patients who had elective or trauma surgery not involving the ankle, who were ASA grade I or II and who were weightbearing immediately postoperatively (without splinting or in a plantigrade boot) had a VTE rate of 0.05% (1 of 1819 patients), compared with 0.67% (10 of 1490 patients, P = .002).
CONCLUSION: Patients not receiving chemical thromboprophylaxis had a low incidence of symptomatic VTE, although they do represent a curated group considered lower risk. Within this group we describe characteristics associated with a substantially lower risk of VTE. All patients should be assessed on an individual basis, and further work is required to substantiate our findings.
The invention relates to health toothpaste prepared from multiple valuable Chinese medicinal materials for preventing and treating oral diseases, which has effects of whitening and fixing teeth, relieving inflammation, inhibiting bacteria, and relieving tooth swelling and pain, oral ulcer, periodontitis and bad breath. The health toothpaste comprises ginseng, fiveleaf gynostemma herb, pseudo-ginseng, borneol and white alum. The health toothpaste has effects of whitening and fixing teeth, relieving inflammation, inhibiting bacteria, relieving tooth swelling and pain, oral ulcer, periodontitis and bad breath, and can be used for treating swelling and pain of teeth, oral ulcer, periodontitis, bad breath and other symptoms. The health toothpaste has effect of treating both principal and secondary aspect of disease, and can achieve the purpose of no recurrence liability after recovery. The health toothpaste also has effects of relieving oral cavity nerve, relieving inflammation and inhibiting bacteria; especially, the health toothpaste can be used for rapidly relieving and preventing oral ulcer, periodontal discomfort and bad breath. The health toothpaste can immediately relieve toothache. Long-term use of the health toothpaste not only has good repairing and health promotion effects on oral cavity cell tissues, but also has the curative effects of treating and preventing gingival hemorrhage, enhancing gingival nutrition, relieving inflammation and swelling, inhibiting bacteria and whitening and fixing teeth. The health toothpaste is suitable for external application, has the effects of diminishing inflammation, detumescence and bacteriostasis, and certain curative effect on scald.
Poales, as one of the largest orders of angiosperm, holds crucial economic and ecological importance. Nevertheless, achieving a consensus topology has been challenging in previous studies due to limited molecular data and sparse taxon sampling. The uneven distribution of species diversity among families and the factors leading to elevated species richness in certain lineages have also been subjects of ongoing discussion and investigation. In this study, we conducted a comprehensive sampling, including representatives from all 14 families and 85 taxa of Poales, along with five additional outgroups. To reconstruct the phylogeny of Poales, we employed a combination of coalescent and concatenation methods on three nuclear gene sets (1093, 491, 143) and one plastid gene set (53), which were inferenced from genomic data. We also conducted phylogenetic hypothesis analyses to evaluate two major conflicting nodes detected in phylogenetic analyses. As a result, we successfully resolved the backbone of Poales and provided a timeline for its evolutionary history. We recovered the sister relationship between Typhaceae and Bromeliaceae as the earliest diverging families within Poales. The clade consisting of Ecdeiocoleaceae and Joinvilleaceae was recovered as the sister group of Poaceae. Within the xyrid clade, Mayacaceae and Erioaculaceae + Xyridaceae successively diverged along the backbone of Poales. The topology of [Aristidoideae, ((Micrairoideae, Panicoideae), (Arundinoideae, (Chloridoideae, Danthonioideae)))] within the PACMAD clade has received strong support from multiple findings. We also delved into the underlying biological factors that contributed to the conflicting nodes observed in the phylogenetic analysis. Apart from the uncertainty regarding the sister group of Poaceae caused by cytonuclear discordance, frequent hybridization and polyploidy may have contributed to other conflicting nodes. We identified 26 putative whole-genome duplication (WGD) events within Poales. However, apart from the σ-WGD and the ρ-WGD, we did not observe any potential polyploid events that could be directly linked to the species diversification in specific lineages. Furthermore, there was a significant increase in the net diversification rate of Poales following the K-Pg boundary.
The participants were informed that they could use the thermophore whenever they felt pain throughout the menstrual cycle. On the first day of the period, they were asked to complete the "Visual Analog Scale" and "Menstrual Symptom Questionnaire" before using the thermophore; apply heat on their sole whenever they felt pain in the first three days of the menstrual period when pain is more intense; rate level of pain twice a day at 12-hour intervals on a daily basis, using the "Visual Analog Scale"; and complete the "Menstrual Symptom Questionnaire" on the last day of the period. On the other hand, the students in the control group completed only the related forms. The students who were previously trained on heat application were trained once again by the researcher as a reminder and then their written consents were obtained through the informed consent form.
There are no adequate and well-controlled studies evaluating leflunomide in pregnant women. However, based on animal studies, leflunomide may increase the risk of fetal death or teratogenic effects when administered to a pregnant woman (see CONTRAINDICATIONS). Women of childbearing potential must not be started on leflunomide until pregnancy is excluded and it has been confirmed that they are using reliable contraception. Before starting treatment with leflunomide, patients must be fully counseled on the potential for serious risk to the fetus.

The patient must be advised that if there is any delay in onset of menses or any other reason to suspect pregnancy, they must notify the physician immediately for pregnancy testing and, if positive, the physician and patient must discuss the risk to the pregnancy. It is possible that rapidly lowering the blood level of the active metabolite by instituting the drug elimination procedure described below at the first delay of menses may decrease the risk to the fetus from leflunomide.

Upon discontinuing leflunomide, it is recommended that all women of childbearing potential undergo the drug elimination procedure described below. Women receiving leflunomide treatment who wish to become pregnant must discontinue leflunomide and undergo the drug elimination procedure described below which includes verification of M1 metabolite plasma levels less than 0.02 mg/L (0.02 µg/mL). Human plasma levels of the active metabolite (M1) less than 0.02 mg/L (0.02 µg/mL) are expected to have minimal risk based on available animal data.
Spherical microcapsules containing biological material such as tissue or living cells are formed with a diameter of less than 300 μm using a microcapsule generating system containing an air knife. The air knife is formed by an air sleeve positioned eccentrically around a needle. An encapsulating material such as an alginate solution containing the biological material to be encapsulated is forced through the needle, while pressurized air is introduced into the air sleeve and flows out an end opening of the sleeve in which the needle is positioned. The pressurized air breaks up the alginate being discharged from the needle. The resultant alginate droplets fall into a collecting tank where they contact a gelling medium, such as CaCl 2 , so that the outer surface of these droplets harden and microcapsules are formed. In addition to being eccentrically positioned to facilitate very small droplet formation, the needle preferably has a beveled, pointed discharge end surface to enhance droplet size reduction. The beveled end surface of the needle preferably extends beyond the end opening of the sleeve and is positioned facing the center of the air sleeve. The end opening of the air sleeve may also be beveled.
BACKGROUND: African sleeping sickness is a neglected tropical disease seldom seen in European travellers.
CASE PRESENTATION: While working in Eastern Africa, a Norwegian man in his sixties developed weakness and fever. He was prescribed doxycycline after a negative malaria rapid test. On the third day of illness he returned to Norway and was admitted to the hospital upon arrival. On admission he was somnolent with fever, tachypnoea, tachycardia, jaundice, a hyperaemic rash, oliguria and haematuria. Blood tests revealed leukopenia, thrombocytopaenia, renal failure and liver dysfunction. Rapid tests were negative for malaria and dengue. Blood microscopy revealed high parasitaemia with trypanosomes indicating human African sleeping-sickness. He had been bitten by a tsetse fly 11 days prior in an area endemic for Trypanosoma brucei gambiense. However, the clinical picture was consistent with Trypanosoma brucei rhodesiense infection (East African sleeping sickness). Four days after starting treatment with suramin, spinal fluid examination revealed mild mononuclear pleocytosis but no visible parasites. Melarsoprol treatment for possible encephalitis was considered but suramin treatment was continued alone. He improved and remains healthy seven years later. PCR on blood was positive for T. b. rhodesiense.
INTERPRETATION: African sleeping sickness can also affect tourists to endemic areas. Onset can be acute, life-threatening and requires treatment with antiparasitic drugs not generally available in Norwegian hospitals.
Novel viral polynucleotide sequences and virus preparations recovered therefrom are provided for use as vaccines. In viruses having long terminal repeats (LTRs). where the LTRs includetranscriptional regulatory functions, at least one of the LTR regions is modified to substantially decrease the activity of at least one locus involved in transcriptional regulation. Specifically, feline leukemia virus (FeLV) is modified in the LTR by deleting at least a portion of an enhancer region and the resulting modified FeLV DNA and modified virus derived therefrom shown to be infectious and capable of inducing an immune response in a mammalian host without the serious pathological symptoms normally associated with FeLV. E. coli strain HB101 (pRF3X) was deposited at the American Type Culture Collection on October 14, 1983 and granted accession no. 39470.
The composition of the present invention contains, as active ingredients, the following ingredients (1) to (4). Ingredient (1): at least one crude drug selected from the group consisting of honey-fried licorice, licorice, Dioscorea japonica Thunberg, jujube, Saccharum granorum and ginseng. Ingredient (2): at least one crude drug selected from the group consisting of Curcuma aromatica, Dimocarpus longan Lour, Curcuma zedoaria Roscoe, Suberect Spatholobus Stem, Luffa cylindria, Sparganium erectum, safflower and Artemisia anomala. Ingredient (3): at least one crude drug selected from the group consisting of tea leaf, Menthae Herba, mulberry leaf, Chrysanthemum morifolium Ramatuelle and Glycine max. Ingredient (4): at least two crude drugs selected from the group consisting of Citrus unshiu Marcow peel, Psoralea corylifolia, Chaenomeles speciosa, Piper longum, cinnamon, Perilla frutescens var. crispa, ginger, coriander, Allium Fistulosum white stem, Ziziphi semen, Platycladus orientalis Franco, Plantago asiatica Linne seed, Plantago asiatica Linne plant, Coicis semen coix seed, corn silk, Bassia scoparia seed, Benincasa hispida seed, Polygonum aviculare, Glechoma hederacea var. grandis, cinnamon, dried ginger, Foeniculum vulgare, Zanthoxylum piperitum, Piper nigrum, Eleutherococcus senticosus and Artemisia princeps Pampanini.
Drug-eluting coronary stents (DES) significantly reduced the rate of neointimal hyperplasia and in-stent restenosis (ISR) compared to bare metal stents (BMS) for the treatment of coronary artery disease. In addition, the continued evolution in scaffold and polymer design with concomitant improvements in antiplatelet therapy has improved the rates of late and very late stent thrombosis. However, despite novel metal scaffold technology, increasing operator experience, and improvement in adjunctive implantation techniques, the incidence of ISR in durable-polymer DES remains a problem, with 1-year rates as high as 12 to 15%.

The outcomes associated with ISR highlight the fact that this is by no means a benign process and studies report MI rates as high as 19.4% with one study demonstrating a total rate of death or nonfatal MI of 3.5%. In addition, ISR presenting as acute coronary syndrome (ACS) has an independent effect on major adverse cardiac events. The emergence of fully bioresorbable vascular scaffolds (BVS) has provided an exciting alternative to combat the long-term structural and functional effects on the coronary vessel seen with implantation of a permanent metal scaffold, regardless of the drug coating. Initial studies have demonstrated the non-inferiority of BVS compared to contemporary DES in regards to death, MI, and MACE. In addition, intravascular imaging has confirmed complete resorbtion of the BVS by 3 years time. The long-term benefits of such technology have yet to be fully assessed. However, based on literature outlining the complicated course of ISR in short-term and that seen in the bare metal stent era, it is projected that complete resorbtion of the vascular scaffold should improve long-term outcomes of patients with ischemic heart disease.

Currently, the clinical presentation, incidence, and outcomes of ISR in contemporary DES are not completely understood. The goal of this particular study is to retrospectively evaluate the long-term impact of ISR over a 10-year period in current contemporary DES. The data can be compared to de novo coronary artery lesions with similar characteristics and complexity to highlight the significant differences in the clinical course of each disease. Ultimately, the investigators will hopefully demonstrate the need for improvement in this arena, which the BVS will potentially provide.
Participants with newly diagnosed systemic AL amyloidosis with Mayo Cardiac Stage II and IIIa cardiac involvement will receive SC daratumumab 1800mg on Day 1 once weekly (q1w) up to Day 22 for cycles 1-2, on Days 1 and 15 for cycles 3-6, and on Day 1 for cycles 7-24 of a 28-day cycle. Participants will also receive VCd (Cyclophosphamide 300 mg/m\^2 either orally or IV, Bortezomib 1.3 mg/m\^2 SC or IV, Dexamethasone 40 mg weekly either orally or IV) starting at Cycle 4 Day 1, weekly (Days 1, 8, 15, 22) in every 28-day cycle for a maximum of 6 cycles (Cycle 9 Day 22).